In this two-part series, John Watkins and Clare Ryder highlight the similarities and differences in global submission requirements.
Regulatory Rapporteur (November 2017)
In this article written by Karen Kaucic, Horacio Plotkin and Christopher Komelasky, the authors discuss how rare disease research can be solved with virtual trials and their supporting technologies.
Applied Clinical Trials (November 2017)
Jonca Bull discusses the significant regulatory actions that have occurred in the rare disease space.
PharmaVOICE (October 2017)
Nicole Stansbury, executive director, discusses risk-based monitoring in the clinical trial industry with CenterWatch Monthly.
CenterWatch Monthly (October 2017)
Regulatory Rapporteur (October 2017)
In this article written by Katie Matys and Janine McKnight, the authors discuss how the right biomarker can make all the difference in a drug-development program.
Genetic Engineering & Biotechnology News (October 2017)
Radek Wasiak of Evidera comments on real-world evidence in part three of this three-part series.
Clinical Leader (September 2017)
Radek Wasiak of Evidera comments on real-world evidence in part two of this three-part series.
In this article written by Denise Moody, Tim King and Ranjit Bains, the authors review an FSP in which PPD reduced a client’s annual operational spend by assuming responsibility for clinical monitoring and site support.
Pharmaceutical Executive (September 2017)
Radek Wasiak of Evidera comments on real-world evidence in part one of this three-part series.
We want to hear from you
Register in PPD's Database
© 2017 Pharmaceutical Product Development, LLC. All rights reserved.